Current status and prospect of pravastatin in pregnancy
10.3760/cma.j.cn113903-20221226-01053
- VernacularTitle:普伐他汀在孕期应用的现状及前景
- Author:
Xiaohong LIN
1
;
Dongyu WANG
;
Lixia SHEN
;
Zilian WANG
Author Information
1. 中山大学附属第一医院产科，广州 510080
- Keywords:
Pravastatin;
Pregnancy complications;
Pre-eclampsia;
Fetal growth retardation
- From:
Chinese Journal of Perinatal Medicine
2023;26(8):696-700
- CountryChina
- Language:Chinese
-
Abstract:
Cholesterol-lowing statins such as pravastatin have been contraindicated in pregnant women for a long time, but recent clinical evidence has demonstrated its safety. Studies have found that pravastatin can correct the imbalance in angiogenesis, reduce vascular inflammation and improve the conditions in patients with placental and maternal vascular dysfunction-related diseases, such as preeclampsia, fetal growth restriction and antiphospholipid syndrome. However, universal administration of pravastatin in pregnancy still requires more evidence on its safety from human clinical trials with larger sample sizes. This article reviews the current situation and prospect of pravastatin in pregnancy.
